Investor Presentation via Engage Investor
Coiled Therapeutics plc announced that its leadership team will host a live interactive presentation on the Engage Investor Platform on Tuesday, October 6, 2026, at 3:00 PM BST. The presentation will provide an update on the company's clinical development program and strategic progress, with opportunities for investors to submit questions in advance or during the event. The company is a clinical-stage precision oncology firm developing small molecule therapies for genetically defined cancers, with its lead program AO-252 being a TACC3 inhibitor currently in a Phase I clinical trial.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that the leadership team will host a live interactive presentation on the Engage Investor Platform on Tuesday 6 October 2026, at 3:00pm BST.
The presentation will be hosted by Dr Sotirios Stergiopoulos, Chairman; Sridhar Vempati, CEO and Stephen West, Non-Executive Director. The Company will provide an update on its clinical development programme and its strategic progress.
The Company welcomes all current shareholders and interested investors to join. Questions may be submitted in advance or at any time during the live presentation.
Investors can register with Engage Investor at no cost, follow the Company from their personalised investor hub and register their interest in attending here: https://engageinvestor.news/COIL_IP1026
About AO-252
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.